

# DIGESTIVE DISEASE DAYS

2022

## PROGRAMMA

14 en 15 september

Congrescentrum NH Koningshof  
Veldhoven



DIGESTIVE DISEASE DAYS - DDD

## **Het programma van de DDD Online werd samengesteld met inbreng van de volgende verenigingen en secties:**

Nederlandse Vereniging voor Gastro-enterologie  
Nederlandse Vereniging voor Gastrointestinale Chirurgie  
Nederlandse Vereniging voor Hepatologie  
Nederlandse Vereniging van Maag-Darm-Leverartsen

### **Secties:**

Sectie Gastrointestinale Endoscopie  
Sectie Neurogastroenterologie en Motiliteit  
Sectie Gastrointestinale Oncologie  
Sectie Inflammatoire Darmziekten IBD  
Sectie Kinder-MDL  
Verpleegkundigen & Verzorgenden Nederland – MDL  
PhD Netwerk

## INHOUDSOPGAVE

pag.

### Woensdag 14 september 2022

Symposium NVIG / NVCO I – Brabantzaal	6
Opening en President Select – Brabantzaal	6
NVGE Invited speakers – Brabantzaal	7
Abstractsessie Nederlandse Vereniging voor Gastrointestinale Chirurgie – Brabantzaal	7
Symposium NVGIC / NVCO II – Brabantzaal	8
Symposium NVGIC / NVCO III – Brabantzaal	9
Best abstracts NVGE 2022 – Brabantzaal	9
Symposium Precision medicine in IBD – Auditorium	11
Abstractsessie Sectie Gastrointestinale Oncologie – Auditorium	11
Symposium Secties Gastrointestinale Oncologie en Sectie IBD – Auditorium	12
Symposium NVH / NVGE – Auditorium	13
Abstractsessie Sectie Inflammatoire Darmziekten – Baroniezaal	13
Abstractsessie Sectie Gastrointestinale Chirurgie – Parkzaal	16
Meet the expert sessie – Zaal 80	17
Programma postersessies I - III	17

### Tijdstippen diverse ledenvergaderingen woensdag:

Nederlandse Vereniging voor Gastroenterologie      14 september, 12.30 uur Brabantzaal

## INHOUDSOPGAVE

pag.

### Donderdag 15 september 2022

ALV Nederlandse Vereniging van Maag-Darm-Leverartsen – Zaal 80	21
PhD-netwerk – Auditorium	21
Video symposium Sectie Gastrointestinale Endoscopie – Auditorium	21
Symposium Neurogastroenterologie en Motiliteit – Auditorium	21
Abstractsessie Sectie Gastrointestinale Endoscopie – Auditorium	22
Wrap up – Auditorium	23
Symposium Groene MDL: wat kan JIJ doen? – Auditorium	23
NVMDL i.o. Collegetour MDL; extracullair verdiepen – Baroniezaal	23
Voortgangstoets en NOVUM – Baroniezaal	24
Abstractsessie Nederlandse Vereniging voor Hepatologie – Baroniezaal	24
E-learning Voeding – Baroniezaal	25
Symposium Bariatrie: wat moet de MDL-arts weten – Baroniezaal	26
Niet-alcoholische leververvetting (NAFLD) – Parkzaal	27
Sectie Gastrointestinale Endoscopie - How to do it video's - Parkzaal	27
Programma V&VN MDL	28
Postersessies IV & V	32

### Tijdstippen diverse ledenvergaderingen donderdag

Nederlandse Vereniging voor Gastroenterologie	15 september, 08.00 uur Zaal 80
Nederlandse Vereniging voor Hepatologie	15 september, 13.15 uur Baroniezaal

## **Belangrijke mededeling over de aanwezigheid van farmaceutische industrieën**

Aan alle deelnemers tijdens de Digestive Disease Days op 14 en 15 september 2022

De Nederlandse Vereniging voor Gastroenterologie kent een jarenlange samenwerking met de farmaceutische industrie. De vereniging stelt de farmaceutische industrie in de gelegenheid aanwezig te zijn bij de wetenschappelijke vergaderingen met een stand. Mede hierdoor kan de vereniging haar wetenschappelijke bijeenkomsten organiseren.

De Geneesmiddelenwet zegt dat - onder strikte voorwaarden - de farmaceutische industrie alleen reclame mag maken voor receptgeneesmiddelen voor personen die bevoegd zijn om dergelijke geneesmiddelen voor te schrijven. Alle andere personen (inclusief bijvoorbeeld verpleegkundigen, endoscopie-assistenten en biochemici) worden beschouwd als "publiek". De farmaceutische industrie mag geen reclame maken voor receptgeneesmiddelen voor publiek.

De Nederlandse Vereniging voor Gastroenterologie is een wetenschappelijke vereniging voor personen die beroepsmatig betrokken zijn bij zorg, onderwijs en onderzoek ten behoeve van patiënten met maag-darm- en leveraandoeningen. Dat betekent dat ook personen die geen arts zijn, lid van de NVGE zijn. De aanwezigheid van artsen, niet-artsen en farmaceutische industrieën tijdens het congres kan de NVGE ongewild in aanraking brengen met de inspectie voor de gezondheidszorg, sectie reclametoezicht, en daarmee in diskrediet worden gebracht. Dat willen wij uiteraard voorkomen.

In verband met de Gedragscode Geneesmiddelenreclame van de CGR en de aan het NVGE-congres verbonden expositie van farmaceutische producten, medische instrumenten en voedingsmiddelen, zal bij uw congresregistratie via de NVGE-website worden gevraagd naar uw bevoegdheid om medicijnen voor te schrijven.

Alle congresdeelnemers dragen verplicht een congresbadge waarop behalve de naam ook beroep/ functie staat aangegeven. Farmaceutische standhouders benaderen uitsluitend congresdeelnemers die de bevoegdheid hebben om receptgeneesmiddelen voor te schrijven of ter hand te stellen. Om dit extra te verduidelijken zal wederom worden gekozen voor verschillende kleuren congresbadges.

Uit het bovenstaande volgt dat aanwezige reclame-uitingen en merkproductinformatie van farmaceutische industrieën alleen gericht zijn op personen die bevoegd zijn om de betreffende geneesmiddelen voor te schrijven. Wij maken u erop attent dat het voor niet-artsen dan ook niet is toegestaan de stands van de aanwezige farmaceutische industrieën te bezoeken.

De NVGE en farmaceutische industrie (sponsoren) vertrouwen erop u met bovenstaande voldoende te hebben geïnformeerd.

Bestuur van de NVGE

WOENSDAG 14 SEPTEMBER 2022

**Symposium NVGIC / NVCO I**

**Brabantzaal**

**Thema:** **Veranderende paradigma's bij de behandeling van GI tumoren**

Voorzitters: *A. van der Bilt en C. Hoff*

09.30 HIPEC bij maagcarcinoom  
*Dr. J.W. van Sandick, chirurg, Antonie van Leeuwenhoek, Amsterdam*

Neoadjuvante therapie bij locally advanced rectumcarcinoom  
*Dr. B. van Etten, chirurg, UMC Groningen*

Neoadjuvante therapie bij het vroeg stadium rectumcarcinoom  
*Prof. dr. H. de Wilt, chirurg, Radboumc, Nijmegen*

10.45 Koffie-/theepauze in de expositiehal

**Opening en President Select**

**Brabantzaal**

Voorzitters: *C.J. van der Woude en A.E. van der Meulen*

11.15 A randomized non-inferiority trial comparing two versus five days of intravenous antibiotics after appendectomy for complex appendicitis.  
*E.M.L. de Wijkerslooth<sup>1</sup>, E.G. Boerm<sup>2</sup>, C.C. van Rossem<sup>3</sup>, J. van Rosmalen<sup>4</sup>, C.I.M. Baeten<sup>5</sup>, F.H. Beverdam<sup>6</sup>, J.W.A.M. Bosmans<sup>2</sup>, E.C.J. Consten<sup>7</sup>, J.W.T. Dekker<sup>8</sup>, M. Emous<sup>9</sup>, A.A.W. van Geloven<sup>10</sup>, A.F. Gijzen<sup>11</sup>, L.A. Heijnen<sup>12</sup>, A.P. Jairam<sup>13</sup>, D.C. Melles<sup>14</sup>, A.P.T. van der Ploeg<sup>3</sup>, P. Steenvoorde<sup>11</sup>, B.R. Toorenvliet<sup>15</sup>, M. Vermaas<sup>16</sup>, B. Wiering<sup>17</sup>, B.P.L. Wijnhoven<sup>1</sup>, A.L. van den Boom<sup>1</sup>, <sup>1</sup>Dept. of Surgery, Erasmus MC - University Medical Center, Rotterdam, <sup>2</sup>Dept. of Surgery, Zuyderland MC, Heerlen, <sup>3</sup>Dept. of Surgery, Maasstad Ziekenhuis, Rotterdam, <sup>4</sup>Dept. of Biostatistics, Erasmus MC - University Medical Center, Rotterdam, <sup>5</sup>Dept. of Surgery, Groene Hart Ziekenhuis, Gouda, <sup>6</sup>Dept. of Surgery, Franciscus Gasthuis & Vlieland, Rotterdam, <sup>7</sup>Dept. of Surgery, Meander MC, Amersfoort, <sup>8</sup>Dept. of Surgery, Reinier de Graaf Gasthuis, Delft, <sup>9</sup>Dept. of Surgery, MC Leeuwarden, Leeuwarden, <sup>10</sup>Dept. of Surgery, Tergooi MC, Hilversum, <sup>11</sup>Dept. of Surgery, Medisch Spectrum Twente, Enschede, <sup>12</sup>Dept. of Surgery, Noordwest Ziekenhuisgroep, Alkmaar, <sup>13</sup>Dept. of Surgery, Catharina Ziekenhuis, Eindhoven, <sup>14</sup>Dept. of Medical Microbiology, Meander MC, Amersfoort, <sup>15</sup>Dept. of Surgery, Ikazia Ziekenhuis, Rotterdam, <sup>16</sup>Dept. of Surgery, IJsselland Ziekenhuis, Capelle a/d IJssel, <sup>17</sup>Dept. of Surgery, Slingeland Ziekenhuis, Deventer, The Netherlands.*

## WOENSDAG 14 SEPTEMBER 2022

- 11.24 Octreotide significantly reduces transfusion requirements compared to standard care in patients with angiodyplasia-related anaemia: a multicentre randomised controlled trial  
*L.C.M.J. Goltstein<sup>1</sup>, L.H.P. Bernts<sup>1</sup>, K.V. Grooteman<sup>1</sup>, R.C.H. Scheffer<sup>2</sup>, R.J.F. Laheij<sup>3</sup>, L.P.L. Gilissen<sup>4</sup>, R.W.M. Schrauwen<sup>5</sup>, N.C. Talstra<sup>5</sup>, A.T. Zuur<sup>6</sup>, H. Braat<sup>7</sup>, M. Hadithi<sup>8</sup>, J.T. Brouwer<sup>9</sup>, W.B. Nagengast<sup>10</sup>, F.A. Oort<sup>11</sup>, J. Tenthof van Noorden<sup>12</sup>, W. Kievit<sup>13</sup>, E.J.M. van Geenen<sup>1</sup>, J.P.H. Drenth<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Elisabeth-Tweesteden Hospital, Tilburg, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Bernhoven Hospital, Uden, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Tjongerschans Hospital, Heerenveen, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, <sup>10</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, <sup>12</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, <sup>13</sup>Dept. of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.*
- 11.33 Rifaximin stimulates nitrogen detoxification in a PXR-independent manner in human small intestinal organoids  
*K. de Wit<sup>1</sup>, U. Beuers<sup>1</sup>, R.B. Takkenberg<sup>1</sup>, S.W.C. van Mil<sup>2</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>2</sup>Center for Molecular Medicine, UMC Utrecht, The Netherlands.*
- 11.42 Uitreiking beste endoscopie video

### NVGE - Invited speakers

### Brabantzaal

- 11.50 Early rectal cancer: diagnostics and treatment  
*Dr. A. Haji, Clinical Director for Surgery, King's College Hospital, London, UK  
Dr. J.J. Boonstra, MDL-arts, Leids Universitair Medisch Centrum, The Netherlands*
- 12.30 Algemene ledenvergadering NVGE
- 12.45 Lunch in de expositiehal en gemodereerde postersessies

### Abstractsessie Nederlandse Vereniging voor Gastrointestinale Chirurgie

### Brabantzaal

Voorzitters: *P. van Duijvendijk en J.J. Atema*

Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie.

- 13.45 External validation of a nomogram predicting conditional survival after curative treatment of esophageal cancer  
*N. Schuring<sup>1</sup>, N.E. Donlon<sup>2</sup>, E.R.C. Hagens<sup>1</sup>, C. Donohoe<sup>2</sup>, M.I. van Berge Henegouwen<sup>3</sup>, J.V. Reynolds<sup>2</sup>, S.S. Gisbertz<sup>1</sup>, <sup>1</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of*

## WOENSDAG 14 SEPTEMBER 2022

Surgery, St James's Hospital, Dublin, Ierland. <sup>3</sup>Dept. of Gastrointestinal Surgery, Amsterdam UMC, Amsterdam, The Netherlands.

- 13.54 Hospital variation in feeding jejunostomy policy for minimally invasive esophagectomy; population-based results from the Dutch Upper gastrointestinal Cancer Audit (DUCA)  
M.R. Visser<sup>1</sup>, D.M. Voeten<sup>2</sup>, J. Straatman<sup>2</sup>, S.S. Gisbertz<sup>2</sup>, J.P. Ruurda<sup>1</sup>, D.L. van der Peet<sup>2</sup>, M.I. van Berge Henegouwen<sup>2</sup>, R. van Hillegersberg<sup>1</sup>, <sup>1</sup>Dept. of Surgery, UMC Utrecht, <sup>2</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
- 14.03 Gecombineerde Vena Porta en Vena Hepatica Embolizatie (PVE/HVE) voor versnelde hypertrofie van de toekomstige restlever – Interim analyse van de DRAGON I  
R. Korenblik<sup>2</sup>, J. Smits<sup>1</sup>, <sup>1</sup>Dept. of Surgery, MUMC+, Maastricht, <sup>2</sup>Dept. of Surgery, MUMC, Maastricht, The Netherlands.
- 14.12 Management of anastomotic leakage after robot-assisted minimally invasive esophagectomy with intrathoracic anastomosis  
E.M. de Groot, L. Goense, S.F.C. Bronzwaer, B.F. Kingma, S. van der Horst, J.W. van den Berg, J.P. Ruurda, R. van Hillegersberg, Dept. of Gastrointestinal Surgery, UMC Utrecht, Utrecht, The Netherlands.
- 14.21 Metastasectomy or stereotactic radiotherapy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study  
T.E. Kroese<sup>1</sup>, N. Jorritsma<sup>1</sup>, H.W.M. van Laarhoven<sup>2</sup>, R. Verhoeven<sup>2</sup>, S. Mook<sup>3</sup>, J.P. Ruurda<sup>1</sup>, P.S.N. van Rossum<sup>3</sup>, R. van Hillegersberg<sup>1</sup>, <sup>1</sup>Dept. of Surgery, UMC Utrecht, Utrecht, <sup>2</sup>Dept. of Medical Oncology, Amsterdam UMC, Amsterdam, <sup>3</sup>Dept. of Radiotherapy, UMC Utrecht The Netherlands.
- 14.30 Long-term complications after distal pancreatectomy: a nationwide analysis  
E.A. van Bodegraven, Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
- 14.39 Samenvatting programma
- 14.45 Einde van deze sessie

Symposium	NVGIC / NVCO II	Brabantzaal
-----------	-----------------	-------------

Voorzitters: O.W. Bastian en G.L. Beets

**Thema:** **“Non”-adenocarcinoom in het gastro-intestinale stelsel**

- 14.45 Neuro-endocriene pancreas tumoren  
Dr. D.J. van Beek, arts-onderzoeker, UMC Utrecht
- 15.05 HCC  
Dr. M.J. Coenraad, MDL-arts, Leids Universitair Medisch Centrum
- 15.25 Sarcomen  
Dr. W. van Houdt, chirurg-oncoloog, Antoni van Leeuwenhoek, Amsterdam
- 15.45 Koffie-/theepauze in de expositiehal

WOENSDAG 14 SEPTEMBER 2022

**Symposium NVGIC / NVCO III**

**Brabantzaal**

Voorzitters: *T. van Loon en M. Westerterp*

**Thema:** **IBD ICC-Symposium 'De patiënt centraal'**

16.15 Sexualiteit en IBD  
*Dr. Y. Reisman, uroloog / seksuoloog, Flare-Health, Amsterdam*

16.40 Maakt de Kono-S zijn beloftes waar? Ervaring met de Kono-S anastomose  
*Dr. M. Richir, oncologisch chirurg, UMC Utrecht*

17.05 Casuïstiek  
*A.R.M. van der Bilt, fellow gastro-intestinal surgery and surgical oncology, UMCG*

17.30 Einde programma, aansluitend Best Abstract sessie

**Best abstracts NVGE 2022**

**Brabantzaal**

Voorzitters: *L.P.S. Stassen en P.P.J. van der Veen*

*Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie.*

17.30 Outcomes of percutaneous cholecystostomy in high-risk patients with acute cholecystitis  
*A.G. Overdevest<sup>1</sup>, B.M. Zonderhuis<sup>2</sup>, J.J.J. de Vries<sup>3</sup>, O.M. van Delden<sup>3</sup>, M.G. Besselink<sup>2</sup>, P. Fockens<sup>1</sup>, R.P. Voermans<sup>1</sup>, R.L.J. van Wanrooij<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>3</sup>Dept. of Radiology, Amsterdam UMC, Amsterdam, The Netherlands.*

17.39 Pancreatoscopy-guided electrohydraulic lithotripsy for the treatment of obstructive distal main pancreatic duct stones; long-term outcomes  
*F.E.M. de Rijk<sup>1</sup>, P.M.C. Stassen<sup>1</sup>, M.A. Boermeester<sup>2</sup>, Y. Issa<sup>2</sup>, M.A. Kempeneers<sup>2</sup>, R.C. Verdonk<sup>3</sup>, M.J. Bruno<sup>1</sup>, P.J.F. de Jonge<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Surgery, Amsterdam UMC, location University of Amsterdam, Amsterdam, <sup>3</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands.*

17.48 Dietary patterns are reflected in the plasma inflammatory proteome of patients with inflammatory bowel disease  
*A.R. Bourgonje<sup>1</sup>, L.A. Bolte<sup>1</sup>, L.L.C. Vranckx<sup>1</sup>, L.M. Spekhorst<sup>1</sup>, R. Gacesa<sup>1</sup>, S. Hui<sup>1</sup>, H.M. van Dullemen<sup>1</sup>, M.C. Visschedijk<sup>1</sup>, E.A.M. Festen<sup>1</sup>, J.N. Samsom<sup>2</sup>, G. Dijkstra<sup>1</sup>, R.K. Weersma<sup>1</sup>, M.J.E. Campmans-Kuijpers<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, <sup>2</sup>Dept. of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands.*

- 17.57** The socioeconomic impact of irritable bowel syndrome: an analysis of direct and indirect healthcare costs in the Netherlands  
*M.H.M.A. Bosman<sup>1</sup>, Z.Z.R.M. Weerts<sup>1</sup>, J.T.W. Snijkers<sup>1</sup>, L. Vork<sup>1</sup>, Z. Mujagic<sup>1</sup>, M.A.M. Hesselink<sup>1</sup>, C. Leue<sup>2</sup>, J.W. Kruimel<sup>1</sup>, J.W.M. Muris<sup>3</sup>, A.A.M. Mascllee<sup>1</sup>, D.M.A.E. Jonkers<sup>1</sup>, D. Keszhelyi<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, <sup>2</sup>Dept. of Psychiatry, Maastricht University Medical Center+, Maastricht, <sup>3</sup>Dept. of General practice and elderly care medicine, Maastricht University, Maastricht, The Netherlands.*
- 18.06** Short and long-term oncological outcomes in screen-detected T1 colorectal cancer: a multicentre cohort study  
*L. van der Schee<sup>1</sup>, K.J.C. Haasnoot<sup>1</sup>, K.M. Gijsbers<sup>1</sup>, S. Elias<sup>2</sup>, F. ter Borg<sup>3</sup>, R.W.M. Schrauwen<sup>4</sup>, A. van Berkel<sup>5</sup>, W.H. de Vos tot Nederveen Cappel<sup>6</sup>, K. Kessels<sup>7</sup>, J.S. Terhaar sive Droste<sup>8</sup>, M.B.W.M. Spanier<sup>9</sup>, F. Boersma<sup>10</sup>, Y.A. Alderlieste<sup>11</sup>, R.M. Schreuder<sup>12</sup>, T.C.J. Seerden<sup>13</sup>, G. Rasschaert<sup>13</sup>, F.P. Vleggaar<sup>1</sup>, M.M. Laclé<sup>14</sup>, L.M.G. Moons<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, <sup>2</sup>Dept. Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Deventer Hospital, Deventer, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Bernhoven Hospital, Uden, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Noordwest Hospital, Alkmaar, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Isala Clinics, Zwolle, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Antonius Hospital, Nieuwegein, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Beatrix Hospital, Gorinchem, <sup>12</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Amphia Hospital, Breda, <sup>14</sup>Dept. of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands.*
- 18.15** Informele afsluiting in de expositiehal
- 19.30** Diner in de Beneluxhal
- 22.00** Koffie/thee in Meierij foyer, informeel netwerken

## WOENSDAG 14 SEPTEMBER 2022

Symposium	Precision medicine in IBD	Auditorium
Voorzitters:	M. Duijvestein en D. van Asseldonk	
9.30	TDM of biological therapies Dr. K. Gecse, MDL-arts, Amsterdam UMC	
9.55	Omics in IBD care Prof. dr. R.K. Weersma, MDL-arts, UMC Groningen	
10.20	Drug positioning in IBD: clues in special patient populations Dr. A.C. de Vries, MDL-arts, Erasmus MC, Rotterdam	
10.45	Koffie-/theepauze in de expositiehal	
Abstractsessie Sectie Gastrointestinale Oncologie		Auditorium
Voorzitters:	J. Westerhof en K.V. Grooteman	
	Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie.	
13.45	Development and validation of a remote monitoring tool for real-world assessment of mild, moderate, and severe infections in Inflammatory Bowel Disease patients A. Rezazadeh Ardabili <sup>1</sup> , D.E.J.M. van Esser <sup>1</sup> , D.S.J. Wintjens <sup>1</sup> , M. Cilissen <sup>1</sup> , D.S. Deben <sup>2</sup> , Z. Mujagic <sup>3</sup> , F. Russ <sup>4</sup> , L.P.S. Stassen <sup>5</sup> , A.A. van Bodegraven <sup>4</sup> , D.R. Wong <sup>2</sup> , B. Winkens <sup>6</sup> , D.M.A.E. Jonkers <sup>1</sup> , M.J.L. Romberg-Camps <sup>7</sup> , M.J. Pierik <sup>8</sup> , <sup>1</sup> Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, <sup>2</sup> Dept. of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Sittard-Geleen, <sup>3</sup> Dept. Of Gastrointestinal Surgery, Maastricht University Medical Center+, Maastricht, <sup>4</sup> Dept. of Gastroenterology and Hepatology, Zuyderland Medical Centre, Sittard-Geleen, <sup>5</sup> Dept. of Surgery, Maastricht University Medical Center+, Maastricht, <sup>6</sup> Dept. of Epidemiology, Maastricht University, Maastricht, <sup>7</sup> Dept. of Gastroenterology, Hepatology and Endocrinology, Zuyderland Medical Centre, Sittard-Geleen, <sup>8</sup> Dept. of Gastroenterology, Hepatology and Endocrinology, Maastricht University Medical Center+, Maastricht, The Netherlands.	
13.54	Transition readiness in adolescents with IBD; Translation and Validation of the Transition Readiness Assessment Questionnaire (TRAQ-NL) M.A.C. van Gaalen <sup>1</sup> , E. van Gijn <sup>1</sup> , M. van Pietersen <sup>1</sup> , L. de Ridder <sup>1</sup> , D. Rizopoulos <sup>2</sup> , J.C. Escher <sup>1</sup> , <sup>1</sup> Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Erasmus MC Sophia's Children hospital, Rotterdam, <sup>2</sup> Dept. of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands.	
14.03	Impact of fecal immunochemical test screening on colorectal cancer incidence and mortality F.E.R. Vuik <sup>1</sup> , P. Wisse <sup>1</sup> , W. de Klaver <sup>2</sup> , S.A.V. Nieuwenburg <sup>1</sup> , N.S. Erler <sup>3</sup> , I. Lansdorp-Vogelaar <sup>4</sup> , E.J. Kuipers <sup>5</sup> , E. Dekker <sup>2</sup> , M.C.W. Spaander <sup>5</sup> , <sup>1</sup> Dept. of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, <sup>2</sup> Dept. of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, <sup>3</sup> Dept. of Biostatistics, Erasmus University Medical Center, Rotterdam, <sup>4</sup> Dept. of Public Health, Erasmus University Medical	

Center, Rotterdam, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

- 14.12 Screening for metachronous esophageal second primary tumors in patients with head and neck cancer  
*L. van Tilburg<sup>1</sup>, S.E.M. van de Ven<sup>1</sup>, P.J.F. de Jonge<sup>1</sup>, W. de Graaf<sup>1</sup>, M.C.W. Spaander<sup>1</sup>, S. Nikkessen<sup>1</sup>, J.A. Hardillo<sup>2</sup>, A. Sewnaik<sup>2</sup>, D.A. Monserez<sup>2</sup>, H. Mast<sup>2</sup>, S. Keereweer<sup>2</sup>, M.J. Bruno<sup>1</sup>, R.J. Baatenburg de Jong<sup>2</sup>, A.D. Koch<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, Rotterdam, The Netherlands.*
- 14.21 Rectal preservation and short-term follow-up after endoscopic intermuscular dissection (EID) for deep submucosal invasive rectal cancer  
*L. van der Schee<sup>1</sup>, S.C. Albers<sup>2</sup>, M.C. Richir<sup>3</sup>, R. Hompes<sup>3</sup>, E. Dekker<sup>2</sup>, J.B. Tuynman<sup>4</sup>, P. Didden<sup>1</sup>, M.M. Laclé<sup>5</sup>, A. Farina Sarasqueta<sup>6</sup>, B.A.J. Bastiaansen<sup>2</sup>, L.M.G. Moons<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, <sup>3</sup>Dept. of Surgery, University Medical Centre Utrecht, Utrecht, <sup>4</sup>Dept. of Surgery, Amsterdam University Medical Centres, Amsterdam, <sup>5</sup>Dept. of Pathology, University Medical Centre Utrecht, Utrecht, <sup>6</sup>Dept. of Pathology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.*
- 14.30 An Objective, Fully Automated Barrett's Risk Prediction Assay Outperforms Pathology in Risk Stratifying Barrett's Esophagus with Low-Grade Dysplasia  
*A.M. Khoshiwall<sup>1</sup>, N.F. Frei<sup>1</sup>, L.C. Duits<sup>1</sup>, R.E. Pouw<sup>1</sup>, E.A. Bossart<sup>2</sup>, R. Critchley-Thorne<sup>2</sup>, J.J.G.H.M. Bergman<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, Castle Biosciences, Pittsburgh, The United States.*
- 14.39 Samenvatting programma
- 14.45 Einde van deze sessie

Symposium	Secties Gastrointestinale Oncologie en Sectie IBD	Auditorium
Voorzitters:	J. Westerhof, M.C. Visschedijk en F.D.M van Schaik	
Thema:	<b>Checkpoint-inhibitor gerelateerde aandoeningen</b>	
14.45	Checkpoint inhibitors: werking, indicatiegebied, wat te verwachten voor de nabije toekomst? Dr. J. de Haan, internist-oncoloog, UMC Groningen	
15.05	Checkpoint-inhibitor-geïnduceerde colitis Dr. F.D.M. van Schaik, MDL-arts, UMC Utrecht	
15.25	Checkpoint-inhibitor-geïnduceerde hepatitis/pancreatitis Dr. M. Visschedijk, MDL-arts, UMC Groningen Dr. H. Blokzijl, MDL-arts, UMC Groningen	
15.45	Koffie-/theepauze in de expositiehal	

WOENSDAG 14 SEPTEMBER 2022

**Symposium NVH / NVGE**

**Auditorium**

Voorzitter: *C. Buis en aios*

**Thema:** **Nieuwe en aangepaste indicaties voor levertransplantatie in Nederland**

16.15      HCC richtsnoer  
*Dr. M.J. Coenraad, MDL-arts, Leids Universitair Medisch Centrum*

Neuroendocriene tumoren  
*Dr. C.M. den Hoed, MDL-arts, Erasmus MC, Rotterdam*

Colorectaal carcinoom metastasen  
*Dr. M.E. Tushuizen, MDL-arts, Leids Universitair Medisch Centrum*

17.30      Einde programma in deze zaal. Plenaire sessie in de Brabantzaal

**Abstractsessie Sectie Inflammatoire Darmziekten**

**Baroniezaal**

Voorzitters: *A.G.L. Bodelier en A.C. de Vries*

*Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie.*

13.45      Real-World Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Two-Year results of the ICC Registry  
*T.S. Straatmijer<sup>1</sup>, V.B.C. Biemans<sup>2</sup>, F. van Schaik<sup>2</sup>, M. Visschedijk<sup>3</sup>, A.C. de Vries<sup>4</sup>, C.Y. Ponsioen<sup>5</sup>, M. Pierik<sup>6</sup>, A.A. van Bodegraven<sup>7</sup>, R. West<sup>8</sup>, K.H.N. de Boer<sup>5</sup>, N. Srivastava<sup>9</sup>, T. Romkens<sup>10</sup>, J. Hoekstra<sup>11</sup>, B. Oldenburg<sup>2</sup>, G. Dijkstra<sup>3</sup>, C.J. van der Woude<sup>4</sup>, M. Lowenberg<sup>5</sup>, Z. Mujagic<sup>6</sup>, A. Bodelier<sup>11</sup>, A.E. van der Meulen<sup>12</sup>, M. Duijvestein<sup>13</sup>, <sup>1</sup>Dept. of Gastroenterology, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, <sup>3</sup>Dept. of Gastroenterology and Hepatology, UMCG, Groningen, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Erasmus mc, Rotterdam, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>6</sup>Dept. of Gastroenterology and Hepatology, MUMC, Maastricht, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Zuyderland, Sittard, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, <sup>9</sup>Dept. Of Gastroenterology and Hepatology, Haaglanden mc, Den Haag, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Amphia ziekenhuis, Breda, <sup>12</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands.*

## WOENSDAG 14 SEPTEMBER 2022

- 13.54 Thioguanine as maintenance therapy for inflammatory bowel disease: A prospective multicenter study  
A. van Bodegraven<sup>2</sup>, D. van Asseldonk<sup>3</sup>, P. van Boeckel<sup>4</sup>, P. Boekema<sup>5</sup>, G. Dijkstra<sup>6</sup>, H. Fidder<sup>7</sup>, I. Gisbertz<sup>8</sup>, F. Hoentjen<sup>9</sup>, B. Jharap<sup>10</sup>, F. Kubben<sup>11</sup>, H. de Leest<sup>12</sup>, M. Russel<sup>13</sup>, M. Meijssen<sup>14</sup>, S. Kaplan<sup>15</sup>, A. Petrak<sup>16</sup>, E. van de Poel<sup>17</sup>, F. Schepers<sup>17</sup>, C. Mulder<sup>18</sup>, K. de Boer<sup>18</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Zuyderland MC, Heerlen, <sup>3</sup>Dept. of Gastroenterology and Hepatology, NWZ, Alkmaar, <sup>4</sup>Dept. of Gastroenterology and Hepatology, St Antonius ziekenhuis, Nieuwegein, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Maxima MC, Eindhoven, <sup>6</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen, <sup>7</sup>Dept. of Gastroenterology and Hepatology, UMCU, Utrecht, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Bernhoven, Bernhoven, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Radboud UMC, Nijmegen, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Meander MC, Amersfoort, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Maasstad, Rotterdam, <sup>12</sup>Dept. of Gastroenterology and Hepatology, Rijnstate ziekenhuis, Arnhem, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Namibië. <sup>14</sup>Dept. of Gastroenterology and Hepatology, Isala, Zwolle, <sup>15</sup>Dept. of Pharmacovigilancy, TEVA, Israël. <sup>16</sup>Dept. of Pharmacovigilancy, TEVA, <sup>17</sup>Dept. Of Pharmacovigilancy, TEVA, Haarlem, <sup>18</sup>Dept. Of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
- 14.03 Mercaptopurine treatment using therapeutic drug monitoring is effective in Ulcerative Colitis: a placebo-controlled randomized trial  
A. Volkers<sup>1</sup>, S. van Gennep<sup>1</sup>, A. Mookhoek<sup>2</sup>, K. de Boer<sup>1</sup>, N. Montazeri<sup>3</sup>, E. Clasquin<sup>1</sup>, M. Duijvestein<sup>4</sup>, A. van Bodegraven<sup>5</sup>, M. Dijkgraaf<sup>6</sup>, S. Rietdijk<sup>7</sup>, J. Jansen<sup>7</sup>, D. van Asseldonk<sup>8</sup>, E. van der Zanden<sup>9</sup>, R. West<sup>10</sup>, G. D'Haens<sup>1</sup>, M. Löwenberg<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Pathology, University of Bern, Zwitserland, <sup>3</sup>Dept. of Biostatistics, Amsterdam UMC, Amsterdam, <sup>4</sup>Dept. of Gastroenterology and Hepatology, RadboudUMC, Nijmegen, <sup>5</sup>Dept. Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, <sup>6</sup>Dept. of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, <sup>7</sup>Dept. of Gastroenterology and Hepatology, OLVG, Amsterdam, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Noordwest ziekenhuisgroep, Alkmaar, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Ziekenhuis Amsteland, Amstelveen, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis, Rotterdam, The Netherlands.
- 14.12 Clinical outcomes of increased versus conventional adalimumab dose intervals in patients with Crohn's disease in stable remission: the randomised controlled LADI trial  
R.C.A. van Linschoten<sup>1</sup>, F.M. Jansen<sup>2</sup>, R.W.M. Pauwels<sup>1</sup>, L.J.T. Smits<sup>2</sup>, F. Atsma<sup>3</sup>, W. Kievit<sup>4</sup>, P.J. Boekema<sup>5</sup>, R.L. West<sup>6</sup>, A.G.L. Bodelier<sup>7</sup>, I.A.M. Gisbertz<sup>8</sup>, F.H.J. Wolfhagen<sup>9</sup>, T.E.H. Römkens<sup>10</sup>, M.W.M.D. Lutgens<sup>11</sup>, A.A. van Bodegraven<sup>12</sup>, B. Oldenburg<sup>13</sup>, M. Pierik<sup>14</sup>, M.G.V.M. Russel<sup>15</sup>, N.K. de Boer<sup>16</sup>, R.C. Mallant-Hent<sup>17</sup>, P.C.J. ter Borg<sup>18</sup>, A.E. van der Meulen<sup>19</sup>, J.M. Jansen<sup>20</sup>, S.V. Jansen<sup>21</sup>, A.C.I.T.L. Tan<sup>22</sup>, C.J. van der Woude<sup>1</sup>, F. Hoentjen<sup>2</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Radboud UMC, Nijmegen, <sup>3</sup>IQ Healthcare, Radboud UMC, Nijmegen, <sup>4</sup>Dept. of Health Evidence, Radboud UMC, Nijmegen, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Maxima MC, Eindhoven, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Amphia Hospital, Breda, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Bernhoven Hospital, Uden, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Elisabeth Tweesteden Hospital, Tilburg,

## WOENSDAG 14 SEPTEMBER 2022

<sup>12</sup>Dept. Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, <sup>13</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, <sup>14</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC+, Maastricht, <sup>15</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Twente, <sup>16</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, <sup>17</sup>Dept. of Gastroenterology and Hepatology, Flevo Hospital, Almere, <sup>18</sup>Dept. of Gastroenterology and Hepatology, Ikazia Hospital, Rotterdam, <sup>19</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, <sup>20</sup>Dept. of Gastroenterology and Hepatology, OLVG Hospital, Amsterdam, <sup>21</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, <sup>22</sup>Dept. of Gastroenterology and Hepatology, CW Hospital, Nijmegen, The Netherlands.

- 14.21 Early anti-TNF results in higher sustained steroid free remission rates without treatment escalation in newly diagnosed paediatric Crohn's disease patients  
R.C.W. Klomberg<sup>1</sup>, H.C. van der Wal<sup>2</sup>, M. Charrout<sup>3</sup>, P. Kemos<sup>4</sup>, F. Ruemmele<sup>5</sup>, N.M. Croft<sup>4</sup>, A. Levine<sup>6</sup>, J.C. Escher<sup>2</sup>, L. de Ridder<sup>2</sup>, <sup>1</sup>Dept. of Pediatrics, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, <sup>2</sup>Dept. of Pediatrics, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, <sup>3</sup>Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands, <sup>4</sup>Dept. of Pediatrics, Queen Mary University of London, London, UK, <sup>5</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Paris, Frankrijk, <sup>6</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, PIBD research center, Wolfson Medical Center, Holon, Israël.
- 14.30 Fecal Microbiota Transplantation with pre-selected donors after budesonide or placebo in patients with active ulcerative colitis: a randomized study  
E. van Lingen<sup>1</sup>, S. Nooitj<sup>2</sup>, E.M. Terveer<sup>2</sup>, S. van der Marel<sup>3</sup>, N. Srivastava<sup>3</sup>, C.J. van der Woude<sup>4</sup>, H.W. Verspaget<sup>1</sup>, A.E. van der Meulen-de Jong<sup>5</sup>, J.J. Keller<sup>3</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept. of Microbiology and Immunology, Leiden University Medical Center, Leiden, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Haaglanden Medisch Centrum, Den Haag, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>5</sup>Dept. of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands.
- 14.39 HLA-DR+CD38+ effector T helper cells distinguish Crohn's disease-associated perianal fistulas from cryptoglandular fistulas  
L.F. Ouboter<sup>1</sup>, M. Schreurs<sup>1</sup>, T. Abdelaal<sup>2</sup>, S.J. Luk<sup>3</sup>, M.C. Barnhoorn<sup>4</sup>, W.E. Huetting<sup>5</sup>, I.J.M. Han-Geurts<sup>6</sup>, K.C.M.J. Peeters<sup>7</sup>, F. Holman<sup>7</sup>, F. Koning<sup>1</sup>, A.E. Van der Meulen-de Jong<sup>4</sup>, M.F. Pascutti<sup>1</sup>, <sup>1</sup>Dept. of Immunology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept. of Radiology, Leiden University Medical Center, Leiden, <sup>3</sup>Dept. of Hematology, Leiden University Medical Center, Leiden, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>5</sup>Dept. of Surgery, Alrijne ziekenhuis, Leiderdorp, <sup>6</sup>Dept. of Surgery, Proctos Clinic, Bilthoven, <sup>7</sup>Dept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
- 14.48 Einde van deze sessie

**Abstractsessie Sectie Gastrointestinale Chirurgie**

**Parkzaal**

Voorzitters: K.M. Govaert en C.M. Marres

Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie.

- 13.45 CD44v6, EpCam, cMet, Rock2 and DUOX2 as targeted biomarkers for the identification of micrometastasis in colon carcinoma  
A.J. Sterkenburg<sup>1</sup>, A.M. van der Waaij<sup>1</sup>, D.J. Sikkenk<sup>2</sup>, A. Karrenbeld<sup>3</sup>, M. Perla<sup>1</sup>, V. Kyritis-kozoglou<sup>1</sup>, E.C.J. Consten<sup>4</sup>, W.B. Nagengast<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMCG, Groningen, <sup>2</sup>Dept. of Surgery, Meander Medical Center, Amersfoort, <sup>3</sup>Dept. of Pathology, UMCG, Groningen, <sup>4</sup>Dept. of Surgery, Meander Medical Center, Groningen, The Netherlands.
- 13.54 Endoscopic submucosal dissection does not affect outcome of completion surgery in early colorectal cancer patients  
N. Dekkers<sup>1</sup>, H. Dang<sup>1</sup>, K. Vork<sup>1</sup>, A.M.J. Langers<sup>1</sup>, J. van der Kraan<sup>1</sup>, M. Westerterp<sup>2</sup>, K.C.M.J. Peeters<sup>3</sup>, F.A. Holman<sup>3</sup>, A.D. Koch<sup>4</sup>, W. de Graaf<sup>4</sup>, P. Didden<sup>5</sup>, L.M.G. Moons<sup>5</sup>, P.G. Doornbosch<sup>6</sup>, J.C.H. Hardwick<sup>1</sup>, J.J. Boonstra<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, <sup>2</sup>Dept. of Gastrointestinal Surgery, Haaglanden Medisch Centrum, Den Haag, <sup>3</sup>Dept. of Gastrointestinal Surgery, LUMC, Leiden, The Netherlands, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, Rotterdam, <sup>5</sup>Dept. of Gastroenterology and Hepatology, UMCU, Utrecht, <sup>6</sup>Dept. of Gastrointestinal Surgery, IJsselland ziekenhuis, Capelle aan den IJssel, The Netherlands.
- 14.03 Gluteal Fasciocutaneous Flap Reconstruction after Salvage Surgery for Pelvic Sepsis  
S.I. Kreisel<sup>1</sup>, S. Sparenberg<sup>2</sup>, S. Sharabiany<sup>2</sup>, R. Hompes<sup>2</sup>, O. Lapid<sup>2</sup>, C.M.A.M. van der Horst<sup>2</sup>, G.D. Musters<sup>2</sup>, P.J. Tanis<sup>2</sup>, <sup>1</sup>Dept. of Gastrointestinal Surgery, Amsterdam University Medical Centre, Amsterdam, <sup>2</sup>Dept. of Surgery, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
- 14.12 Required Distal Mesorectal Resection Margin in Partial Mesorectal Excision: a Systematic Review on Distal Mesorectal Spread  
A.A.J. Grüter<sup>1</sup>, A.S. van Lieshout<sup>1</sup>, S.E. van Oostendorp<sup>1</sup>, J.C.F. Ket<sup>2</sup>, M. Tenhagen<sup>1</sup>, F.C. den Boer<sup>3</sup>, R. Hompes<sup>1</sup>, P.J. Tanis<sup>4</sup>, J.B. Tuynman<sup>1</sup>, <sup>1</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup>Medical Library, Vrije Universiteit, Amsterdam, <sup>3</sup>Dept. of Surgery, Zaans Medical Centre, Zaandam, <sup>4</sup>Dept. of Surgery, Erasmus MC, Rotterdam, The Netherlands.
- 14.21 Risk factors for a permanent stoma after resection of left-sided obstructive colon cancer – A prediction model  
B. Zamaray, Dept. of Gastrointestinal Surgery, Isala ziekenhuis, Zwolle, The Netherlands.
- 14.30 Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991-2020  
L. Heuthorst, Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
- 14.39 Samenvatting programma
- 14.45 Einde van deze sessie

**Meet the expert sessie**

**Zaal 80**

**Thema: Belang van voeding: wat kan een tarwekorrel uitrichten met onze darmen?**

Deze sessie - waarvoor tevoren moet worden ingeschreven - wordt verzorgd door:

Dr. J.W. Kruimel, MDL-arts, en Prof. dr. D.M.A.E. Jonkers, onderzoeker,  
MUMC+, Maastricht

15.45 Koffie-/theepauze in de expositiehal

**Postersessie I**

**Expositiehal**

- 1 Laparoscopic ischemic conditioning prior to esophagectomy in high-risk esophageal cancer patients – a multicenter feasibility trial  
E.M. De Groot<sup>1</sup>, L. Schiffmann<sup>2</sup>, A. Van der Veen<sup>1</sup>, D. Pintos dos Santos<sup>3</sup>, P.A. De jong<sup>4</sup>, B. Babic<sup>5</sup>, C. Bruns<sup>5</sup>, J.P. Ruurda<sup>1</sup>, H. Fuchs<sup>5</sup>, R. Van Hillegersberg<sup>1</sup>, W. Schröder<sup>5</sup>, <sup>1</sup>Dept. of Gastrointestinal Surgery, UMC Utrecht, Utrecht, <sup>2</sup>Dept. of Surgery, University of Cologne, Cologne, Duitsland. <sup>3</sup>Dept. of Radiology, University of Cologne, Cologne, Germany. <sup>4</sup>Dept. of Radiology, UMC Utrecht, Utrecht, Nederland, <sup>5</sup>Dept. of Gastrointestinal Surgery, University of Cologne, Cologne, Germany.
- 2 Surgical treatment of esophago-tracheobronchial fistulas after esophagectomy with gastric conduit reconstruction  
E.M. De Groot<sup>1</sup>, B.F. Kingma<sup>1</sup>, L. Goense<sup>1</sup>, N.P. Van der Kaaij<sup>2</sup>, R.C.A. Meijer<sup>2</sup>, F.Z. Ram-Jankhan<sup>2</sup>, P.A.A. Schellekens<sup>2</sup>, S.A. Braithwaite<sup>3</sup>, M. Marsman<sup>3</sup>, J.P. Ruurda<sup>1</sup>, R. Van Hillegersberg<sup>1</sup>, <sup>1</sup>Dept. of Gastrointestinal Surgery, UMC Utrecht, Utrecht, <sup>2</sup>Dept. of Surgery, UMC Utrecht, Utrecht, <sup>3</sup>Dept. of Anesthesiology, UMC Utrecht, Utrecht, The Netherlands.
- 3 Endoscopic suturing as salvage therapy for anastomosis leakage after colorectal surgery  
J.W.A. Straathof<sup>1</sup>, G.D. Slooter<sup>2</sup>, M.J. ter Borg<sup>1</sup>, C. van den Broek<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maxima MC, Veldhoven, <sup>2</sup>Dept. of Surgery, Maxima MC, Veldhoven, The Netherlands.
- 4 Metachronous peritoneal metastases in patients with pT4b colon cancer: an international multicenter analysis of intraperitoneal versus retroperitoneal tumor invasion  
E.S. Zwanenburg<sup>1</sup>, A.M. Gehrels<sup>1</sup>, V.P. Bastiaenen<sup>1</sup>, A.G.J. Aalbers<sup>2</sup>, A. Arjona-Sanchez<sup>3</sup>, V. Bellato<sup>4</sup>, J.D.W. van der Bilt<sup>5</sup>, A.D. D'Hoore<sup>6</sup>, E. Espinosa-Redondo<sup>3</sup>, C.E.L. Klaver<sup>7</sup>, M. Kusters<sup>1</sup>, I.D. Nagtegaal<sup>8</sup>, B. van Ramshorst<sup>9</sup>, H.C. van Santvoort<sup>9</sup>, G.S. Sica<sup>4</sup>, P. Snaebjornsson<sup>10</sup>, K.A.T.G.M. Wasmann<sup>1</sup>, J.H.W. de Wilt<sup>11</sup>, A.M. Wolthuis<sup>6</sup>, P.J. Tanis<sup>12</sup>, <sup>1</sup>Dept. of Gastrointestinal Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Gastrointestinal Surgery, Netherlands Cancer Institute, Amsterdam, <sup>3</sup>Dept. of Gastrointestinal Surgery, Reina Sofia University Hospital, Cordoba, Spanje. <sup>4</sup>Dept. of Gastrointestinal Surgery, University Hospital Tor Vergata, Rome, Italië. <sup>5</sup>Dept. of Gastrointestinal Surgery, Flevoziekenhuis, Almere, <sup>6</sup>Dept. of Gastrointestinal Surgery, University Hospital Leuven, Leuven, België. <sup>7</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>8</sup>Dept. of Pathology, Radboud University

## WOENSDAG 14 SEPTEMBER 2022

Medical Center, Nijmegen, <sup>9</sup>Dept. of Gastrointestinal Surgery, Sint Antonius Hospital, Nieuwegein, <sup>10</sup>Dept. of Pathology, Netherlands Cancer Institute, Amsterdam, <sup>11</sup>Dept. of Gastrointestinal Surgery, Radboud University Medical Center, Nijmegen, <sup>12</sup>Dept. of Gastrointestinal Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.

- 5 Identification of a distinct microbiota signature in Crohn's disease-associated and cryptoglandular perianal fistulas  
*M.C. Barnhoorn<sup>1</sup>, L.F. Ouboter<sup>1</sup>, Q.R. Ducarmon<sup>2</sup>, E. van Lingen<sup>1</sup>, R.D. Zwittink<sup>2</sup>, L.J.A.C. Hawinkels<sup>1</sup>, M.F. Pascutti<sup>3</sup>, A.E. van der Meulen-de Jong<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, <sup>3</sup>Dept. of Immunology, Leiden University Medical Center, Leiden, The Netherlands.*

	<b>Postersessie II</b>	<b>Expositiehal</b>
6	Contrast-enhanced radiologic evaluation of gastric conduit emptying after esophagectomy <i>M.L. Feenstra<sup>1</sup>, L. Alkemade<sup>1</sup>, J.E. van den Bergh<sup>2</sup>, S.S. Gisbertz<sup>1</sup>, F. Daams<sup>1</sup>, M.I. van Berge Henegouwen<sup>1</sup>, W.J. Eshuis<sup>1</sup>, <sup>1</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup>Dept. of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</i>	
7	Exploring the impact of urogenital organ displacement after abdominoperineal resection on urinary and sexual function <i>S.I. Kreisel<sup>1</sup>, S. Sharabiany<sup>2</sup>, G.J. Strijk<sup>2</sup>, R.D. Blok<sup>2</sup>, J. Bosschieter<sup>2</sup>, E.T.M. Laan<sup>2</sup>, C. Cunningham<sup>3</sup>, R. Hompes<sup>2</sup>, G.D. Musters<sup>2</sup>, P.J. Tanis<sup>2</sup>, <sup>1</sup>Dept. of Gastrointestinal Surgery, Amsterdam University Medical Centre, Amsterdam, <sup>2</sup>Dept. of Surgery, Amsterdam University Medical Centre, Amsterdam, Nederland, <sup>3</sup>Dept. of Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, Verenigd Koninkrijk.</i>	
8	Development and validation of a condition-specific quality of life instrument for adults with esophageal atresia <i>C.A. ten Kate<sup>1</sup>, N.M. Teunissen<sup>1</sup>, J. van Rosmalen<sup>2</sup>, L.S. Kamphuis<sup>3</sup>, M.P. van Wijk<sup>4</sup>, M. Joosten<sup>5</sup>, E.S. van Tuyl van Serooskerken<sup>6</sup>, R. Wijnen<sup>1</sup>, H. IJsselstijn<sup>1</sup>, A.B. Rietman<sup>1</sup>, M.C.W. Spaander<sup>7</sup>, <sup>1</sup>Dept. of Pediatric Surgery, Erasmus University Medical Centre – Sophia Children's Hospital, Rotterdam, <sup>2</sup>Dept. of Biostatistics, Erasmus University Medical Centre, Rotterdam, <sup>3</sup>Dept. of Gastroenterology, Erasmus University Medical Centre, Rotterdam, <sup>4</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Amsterdam UMC – Emma Children's Hospital, University of Amsterdam, Amsterdam, <sup>5</sup>Dept. of Pediatric Surgery, Radboud University Medical Center, Amalia Children's Hospital, Nijmegen, <sup>6</sup>Dept. of Pediatric Surgery, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.</i>	

## WOENSDAG 14 SEPTEMBER 2022

- 9 A Computer-Aided Diagnosis (CADx) system for characterization of Barrett's neoplasia  
J.B. Jukema<sup>1</sup>, C.H.J. Kusters<sup>2</sup>, M.R. Jong<sup>1</sup>, K.N. Fockens<sup>1</sup>, T. Boers<sup>2</sup>, J.A. van der Putten<sup>2</sup>, F. van der Sommen<sup>2</sup>, P.H. de With<sup>2</sup>, A.J. de Groot<sup>1</sup>, J.J.G.H.M. Bergman<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>2</sup>Video Coding and Architectures group, Eindhoven University of Technology, Eindhoven, The Netherlands.
- 10 Incidence of recurrent cholangitis in patients with a non-stenotic hepaticojejunostomy  
B.M. van der Lecq<sup>1</sup>, J.A. Fritzsche<sup>1</sup>, M.A.D. Smit<sup>1</sup>, M.G. Besselink<sup>2</sup>, O.R. Busch<sup>3</sup>, F. Daams<sup>4</sup>, G. Kazemier<sup>4</sup>, J. Langver<sup>1</sup>, C.Y. Ponsioen<sup>5</sup>, R.J. Swijnenburg<sup>2</sup>, B.M. Zonderhuis<sup>4</sup>, R.L.J. van Wanrooij<sup>6</sup>, J.I. Erdmann<sup>2</sup>, R.P. Voermans<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>2</sup>Dept. of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>3</sup>Dept. of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>4</sup>Dept. of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- 11 Random biopsies from the gastro-esophageal junction after complete eradication of Barrett's esophagus: utile or futile?  
C.N. Frederiks<sup>1</sup>, S.N. van Munster<sup>2</sup>, E.A. Nieuwenhuis<sup>3</sup>, L. Alvarez Herrero<sup>2</sup>, A. Alkahafaf<sup>4</sup>, B.E. Schenk<sup>4</sup>, E.J. Schoon<sup>5</sup>, W.L. Curvers<sup>5</sup>, A.D. Koch<sup>6</sup>, P.J.F. de Jonge<sup>6</sup>, T.J. Tang<sup>7</sup>, W.B. Nagengast<sup>8</sup>, J. Westerhof<sup>8</sup>, M.H.M.G. Houben<sup>9</sup>, J.J.G.H.M. Bergman<sup>3</sup>, R.E. Pouw<sup>3</sup>, B.L.A.M. Weusten<sup>2</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands. <sup>2</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands. <sup>3</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>4</sup>Dept. of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands. <sup>6</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands. <sup>7</sup>Dept. of Gastroenterology and Hepatology, IJsselland Hospital, Cappelle aan den IJssel, The Netherlands. <sup>8</sup>Dept. of Gastroenterology and Hepatology, UMC Groningen, Groningen, The Netherlands. <sup>9</sup>Dept. of Gastroenterology and Hepatology, Haga Hospital, Den Haag, The Netherlands.

## Postersessie III

## Expositiehal

- 12 Improving patient-centred cancer care with the Assessment of Burden of ColoRectal Cancer (ABCRC)-tool  
B.J.M. Thomassen<sup>1</sup>, I. te Boome<sup>2</sup>, A.M.J. Somers<sup>2</sup>, C. Graepner<sup>2</sup>, M.L. Kimman<sup>3</sup>, A.H.M. Gidding-Slok<sup>4</sup>, S.O. Breukink<sup>2</sup>, <sup>1</sup>Dept. of Surgery, Maastricht University, Maastricht, <sup>2</sup>Dept. of Surgery, Maastricht University Medical Center, Maastricht, <sup>3</sup>Dept. of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center, Maastricht, <sup>4</sup>Dept. of General practice and elderly care medicine, Maastricht University, Maastricht, The Netherlands.

WOENSDAG 14 SEPTEMBER 2022

- 13 Impact of the COVID-19 pandemic on procedure volumes in gastroenterology: a nationwide study  
M.J. Sonneveld<sup>1</sup>, S. Hardeman<sup>2</sup>, E.J. Kuipers<sup>3</sup>, W. De Graaf<sup>1</sup>, M.C.W. Spaander<sup>3</sup>, A.J.P. Van der Meer<sup>3</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>2</sup>Dutch Healthcare Authority, Newtonlaan 1, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands.
- 14 Benefit of risk-stratified prophylactic treatment on clinical outcome in post-operative Crohn's disease  
V.W. Joustra<sup>1</sup>, J. van Sabben<sup>1</sup>, E. van der Does de Willebois<sup>2</sup>, M. Duijvestein<sup>3</sup>, N. de Boer<sup>1</sup>, J. Jansen<sup>4</sup>, J. van der Bilt<sup>2</sup>, W. Lameris<sup>2</sup>, W. Bemelman<sup>2</sup>, C. Buskens<sup>2</sup>, G.R.A.M. D'Haens<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC locatie AMC, Amsterdam, <sup>2</sup>Dept. of Surgery, Amsterdam UMC locatie AMC, Amsterdam, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
- 15 Fatigue associates with frailty in older patients with Inflammatory Bowel Disease  
A.B. Fons<sup>1</sup>, V.E.R. Asscher<sup>1</sup>, S.N. Waars<sup>1</sup>, R.J.L. Stuyt<sup>2</sup>, A.M.C. Baven-Pronk<sup>3</sup>, S. van der Marel<sup>4</sup>, R.J. Jacobs<sup>5</sup>, J.J.L. Haans<sup>6</sup>, F.J. van Deudekom<sup>7</sup>, S.P. Mooijaart<sup>7</sup>, A.E. van der Meulen-de Jong<sup>1</sup>, K.J. Kalisvaart<sup>8</sup>, P.W.J. Maljaars<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, <sup>2</sup>Dept. of Gastroenterology and Hepatology, HagaZiekenhuis, The Hague, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Groene Hart Ziekenhuis, Gouda, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Haaglanden Medical Centre, The Hague, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Alrijne Hospital, Leiden and Leiderdorp, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, <sup>7</sup>Dept. of Gerontology and Geriatrics, Leiden University Medical Centre, Leiden, <sup>8</sup>Dept. of Gerontology and Geriatrics, Spaarne Gasthuis, Haarlem, The Netherlands.
- 16 The impact of sex on treatment and outcome in relation to histologic subtype in patients with resectable gastric cancer  
I.A. Caspers<sup>1</sup>, A.E. Slagter<sup>2</sup>, P. Lind<sup>3</sup>, K. Sikorska<sup>4</sup>, K. Wiklund<sup>3</sup>, F. Pontén<sup>5</sup>, M. Nordsmark<sup>6</sup>, C.J.H. Van de Velde<sup>7</sup>, E. Meershoek - Klein Kranenbarg<sup>7</sup>, J.W. Van Sandick<sup>8</sup>, E.P.M. Jansen<sup>2</sup>, H.W.M. Van Laarhoven<sup>9</sup>, M. Verheij<sup>10</sup>, N.C.T. Van Grieken<sup>11</sup>, A. Cats<sup>12</sup>, <sup>1</sup>Dept. of Gastroenterology, NKI Antoni van Leeuwenhoek, Amsterdam, <sup>2</sup>Dept. of Radiation Oncology, NKI Antoni van Leeuwenhoek, Amsterdam, <sup>3</sup>Dept. of Medical Oncology, Karolinska institute, Stockholm, Sweden. <sup>4</sup>Dept. of Biometrics, NKI Antoni van Leeuwenhoek, Amsterdam, <sup>5</sup>Dept. of Pathology, Rudbeck Laboratory, Uppsala, Sweden. <sup>6</sup>Dept. of Medical Oncology, Aarhus University Hospital, Aarhus, Denmark. <sup>7</sup>Dept. of Surgery, Leids Universitair Medisch Centrum, Leiden, <sup>8</sup>Dept. of Surgery, NKI Antoni van Leeuwenhoek, Amsterdam, <sup>9</sup>Dept. of Medical Oncology, Amsterdam UMC, Amsterdam, <sup>10</sup>Dept. of Radiation Oncology, Radboud UMC, Nijmegen, <sup>11</sup>Dept. of Pathology, Amsterdam UMC, Amsterdam, <sup>12</sup>Dept. of Gastrointestinal Oncology, NKI Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

DONDERDAG 15 SEPTEMBER 2022

NVMDL	Algemene Ledenvergadering	Zaal 80
08.00	Algemene ledenvergadering NVMDL met ontbijtbuffet	
09.30	Einde vergadering	
PhD-netwerk		Auditorium
Voorzitter:	A.M. van der Waaij	
08.30	Van onderzoeksidé naar uitvoering	
09.30	Einde van deze sessie	
Video symposium Sectie Gastrointestinale Endoscopie		Auditorium
Voorzitter:	volgt	
09.30	Endoscopiesymposium, video's worden becommentarieerd door inzenders	
10.45	Koffie-/theepauze in de expositiehal	
Symposium Neurogastroenterologie en Motiliteit		Auditorium
Voorzitters:	F.B. van Hoeij en Z.Z.R.M. Weerts	
<b>Thema:</b>	<b>Invasieve ingrepen voor functionele aandoeningen: indicatie, techniek en uitkomst</b>	
11.15	POEM voor achalasie <i>Prof. dr. A.J. Bredenoord, MDL-arts, Amsterdam UMC</i>	
11.35	G-POEM voor gastroparesis <i>Dr. J. Conchillo, MDL-arts, Maastricht UMC</i>	
11.55	Coeliacs release bij MALS (CARoSO studie) <i>F. Metz, arts-assistent chirurgie en promovenda, Expertcentrum Maag-Darm Ischemie, Medisch Spectrum Twente</i>	
12.15	Einde van deze sessie, lunchpauze in de expositiehal	

**Abstractsessie Sectie Gastrointestinale Endoscopie**

**Auditorium**

Voorzitters: volgt

Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie

- 12.15 A computer aided detection system for Barret's neoplasia improves neoplasia detection  
*K.N. Fockens<sup>1</sup>, M.R. Jong<sup>1</sup>, J.B. Jukema<sup>1</sup>, T. Boers<sup>2</sup>, K. Kusters<sup>2</sup>, J.A. van der Putten<sup>2</sup>, F. van der Sommen<sup>2</sup>, P.H. de With<sup>2</sup>, A.J. de Groof<sup>1</sup>, J.J.G.H.M. Bergman<sup>1</sup>, <sup>1</sup>Dept. Of Gastroenterology and Hepatology, Amsterdam UMC, loc. VUmc, Amsterdam, <sup>2</sup>Dept. of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.*
- 12.24 Early detection of Barrett's esophagus and esophageal cancer in primary care using transnasal endoscopy: a prospective cohort study  
*L.J. Huibertse, Y. Peters, P.D. Siersema, Dept. of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.*
- 12.33 Long-term efficacy of plastic versus metal stents in inoperable perihilar cholangiocarcinoma; a retrospective cohort study  
*J.A. Fritzsche<sup>1</sup>, D.M. De Jong<sup>2</sup>, J.J.M.M. Borremans<sup>1</sup>, M.J. Bruno<sup>2</sup>, O.M. Van Delden<sup>3</sup>, J.I. Erdmann<sup>4</sup>, P. Fockens<sup>1</sup>, P. De Gooyer<sup>1</sup>, B. Groot Koerkamp<sup>5</sup>, H.J. Klümpen<sup>6</sup>, A. Moelker<sup>7</sup>, L.E. Nooijen<sup>8</sup>, C.Y. Ponsioen<sup>1</sup>, R.L.J. Van Wanrooij<sup>9</sup>, L.M.J.W. Van Driel<sup>2</sup>, R.P. Voermans<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, <sup>3</sup>Dept. of Radiology, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>4</sup>Dept. of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC Cancer Center, Rotterdam, <sup>6</sup>Dept. of Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, <sup>7</sup>Dept. of Radiology, Erasmus University Medical Center, Rotterdam, <sup>8</sup>Dept. of Surgery, Amsterdam UMC location Vrije Universiteit, Amsterdam, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC location Vrije Universiteit, Amsterdam, The Netherlands.*
- 12.42 Endoscopy training in the Netherlands: a national survey among gastroenterologists  
*R.A. Mousset<sup>1</sup>, W.H. de Vos tot Nederveen Cappell<sup>1</sup>, J.P.E.N. Pierie<sup>2</sup>, P.L.P. Brand<sup>3</sup>, A.M.J. Langters<sup>4</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Isala Zwolle, Zwolle, <sup>2</sup>Dept. of Gastrointestinal Surgery, Medisch Centrum Leeuwarden, Leeuwarden, <sup>3</sup>Dept. of Pediatrics, Isala Zwolle, Zwolle, <sup>4</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, The Netherlands.*
- 12.51 Intraductal fully covered self-expanding metal stent versus multiple plastic stents for treating biliary anastomotic strictures after liver transplantation  
*N.J. Sissingh<sup>1</sup>, A. Inderson<sup>1</sup>, A.B. De Vries<sup>2</sup>, B. Van Hoek<sup>1</sup>, F. Van der Heide<sup>2</sup>, J.E. Van Hooft<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept. of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.*

## DONDERDAG 15 SEPTEMBER 2022

- 13.00 Motorized spiral enteroscopy-assisted ERCP in surgically altered upper gastrointestinal anatomy: preliminary experience  
A. Al-Toma<sup>1</sup>, R. Zoutendijk<sup>2</sup>, P. van der Schaaf<sup>1</sup>, P. Stadhouders<sup>1</sup>, W.W. te Riele<sup>3</sup>, W.J.M. Derkxsen<sup>3</sup>, R.C. Verdonk<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, <sup>2</sup>Dept. of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, <sup>3</sup>Dept. of Gastrointestinal Surgery, St Antonius Hospital, Nieuwegein, The Netherlands.
- 13.09 Samenvatting programma
- 13.15 Lunch in de expositiehal en gemodereerde postersessies

### Best of DDD 'Wrap up'

Auditorium

Voorzitter: C.J. van der Woude en A.E. van der Meulen

14.00 Wrap up van de afgelopen twee dagen

### Symposium Groene MDL: wat kan JIJ doen?

Auditorium

Voorzitters: E. van der Zanden, M. Duijvestein en B. Krijnen

15.00 Opening

15.05 Groene MDL: Waar staan we nu?  
M. te Groen, arts-onderzoeker, Radboudumc, Nijmegen

15.15 Groene MDL: de (on)mogelijkheden van infectiepreventie en duurzaamheid  
*To be announced*

15.45 Pitches voorbeelden uit de dagelijkse praktijk

16.00 In kleine werkgroepjes aan de slag:  
Wat kunnen we komend jaar oppakken?

16.20 Samenvatting symposium Groene MDL: wat kan JIJ doen?

16.30 Afsluiting

### NVMDL i.o.

Baroniezaal

Voorzitters: D.S.J. Wintjes en C.M. de Clerk

08.30 **Collegetour MDL: extracurriculair verdiepen**

09.30 Einde van deze sessie

DONDERDAG 15 SEPTEMBER 2022

**Voortgangstoets en NOVUM**

**Baroniezaal**

Voorzitters: *M. Klemt-Kropp en E.H. Wouters-van den Berg*

09.30      NOVUM 1.1 en 2.0  
*Prof. dr. B. Oldenburg, MDL-arts, UMC Utrecht*

10.00      MDL voortgangstoets: do's and don'ts  
*Dr. A.M.J. Langers, MDL-arts, LUMC*

10.30      Prijsuitreiking kennisspel  
*Dr. F.B. van Hoeij, aios MDL, Meander MC*

10.45      Koffie-/theepauze in de expositiehal

**Abstractsessie**

**Nederlandse Vereniging voor Hepatologie**

**Baroniezaal**

Voorzitters: *E.M.M. Kuipers en R.B. Takkenberg*

Voordrachten in het Nederlands, 6 minuten presentatie en 3 minuten discussie

12.15      Comorbidities, information needs and lifestyle changes in patients with NAFLD  
*L.S. Oude Veldhuis<sup>1</sup>, C.H.C. Drossaert<sup>2</sup>, H. ten Berge<sup>2</sup>, M.E.M. den Ouden<sup>1</sup>, J.E.W.C. van Gemert-Pijnen<sup>2</sup>, M.M.J. Guichelaar<sup>3</sup>, <sup>1</sup>Dept. of Health Services Research, Saxion University of Applied Sciences, Enschede, <sup>2</sup>Dept. of Health Psychology, University of Twente, Enschede, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, The Netherlands.*

12.24      Evaluation of medication-related problems in liver transplant recipients with and without an outpatient medication consultation by a clinical pharmacist: a cohort study  
*M.B. Mulder<sup>1</sup>, B. Doga<sup>1</sup>, S.D. Borgsteede<sup>2</sup>, A.M. van den Burg<sup>3</sup>, H.J. Metselaar<sup>3</sup>, C.M. den Hoed<sup>3</sup>, N.G.M. Hunfeld<sup>1</sup>, <sup>1</sup>Dept. of Hospital Pharmacy, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Clinical Pharmacy, Stichting HealthBase, Houten, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands.*

12.33      Ductular bilirubinostasis is a diagnostic biomarker for acute-on-chronic liver failure: results from a well-defined cohort of patients with alcoholic steatohepatitis  
*A.G.C. Broekhoven<sup>1</sup>, T. Ostyn<sup>2</sup>, L. Van Melkebeke<sup>3</sup>, H.W. Verspaget<sup>1</sup>, S. Van der Merwe<sup>3</sup>, J. Verbeek<sup>3</sup>, M.J. Coenraad<sup>1</sup>, T.A. Roskams<sup>2</sup>, F. Nevens<sup>3</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, <sup>2</sup>Dept. Of Pathology, Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium, <sup>3</sup>Dept. of Gastroenterology and Hepatology, University Hospitals, KU Leuven, Leuven, Belgium.*

12.42      The effect of consecutive fecal microbiome transplantation (FMT) on hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD)  
*K.C. Van Son<sup>1</sup>, M.M. Ruissen<sup>2</sup>, J.K. Sont<sup>3</sup>, E.J. Kuijper<sup>3</sup>, E.M. Terveer<sup>3</sup>, J.J. Keller<sup>1</sup>, M.E. Tushuizen<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, <sup>2</sup>Dept. of Internal Medicine, Leiden University Medical Center, Leiden, <sup>3</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.*

## DONDERDAG 15 SEPTEMBER 2022

- 12.51 Three-year results of renal function in De Novo liver transplant recipients with low-dose sirolimus and tacrolimus versus normal-dose tacrolimus: multicenter randomized, controlled trial  
M. .B. Mulder<sup>1</sup>, B. van Hoek<sup>2</sup>, A.P. van den Berg<sup>3</sup>, W.G. Polak<sup>4</sup>, I.P.J. Alwayn<sup>5</sup>, K.P. de Jong<sup>6</sup>, B.C.M. de Winter<sup>1</sup>, E. Verhey-Hart<sup>7</sup>, N.S. Erler<sup>8</sup>, C.M. den Hoed<sup>7</sup>, H. J. Metselaar<sup>7</sup>, <sup>1</sup>Dept. of Hospital Pharmacy, Erasmus MC, Rotterdam, <sup>2</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, <sup>3</sup>Dept. of Gastroenterology and Hepatology, UMCG, Groningen, <sup>4</sup>Dept. of Surgery, Erasmus MC, Rotterdam, <sup>5</sup>Dept. of Surgery, LUMC, Leiden, <sup>6</sup>Dept. of Surgery, UMCG, Groningen, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>8</sup>Dept. of Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
- 13.00 Dietary Dicarbonyls and Intestinal Inflammation in Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients  
M.C.G. de Graaf<sup>1</sup>, J.L.J.M. Scheijen<sup>2</sup>, C.E.G.M. Spooren<sup>1</sup>, Z. Mujagic<sup>1</sup>, M.J. Pierik<sup>1</sup>, D. Keszthelyi<sup>1</sup>, C.G. Schalkwijk<sup>2</sup>, D.M.A.E. Jonkers<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, <sup>2</sup>Dept. of Internal Medicine , Maastricht University Medical Center+, Maastricht, The Netherlands.
- 13.09 General life satisfaction in IBS patients is associated with psychological symptom burden and quality of life, rather than gastrointestinal symptom severity  
J.T.W. Snijkers<sup>1</sup>, B. Winkens<sup>2</sup>, Z.Z.R.M. Weerts<sup>1</sup>, L. Vork<sup>1</sup>, Z. Mujagic<sup>1</sup>, M.A.M. Hesselink<sup>1</sup>, C. Leue<sup>3</sup>, J.W. Kruimel<sup>1</sup>, J.W.M. Muris<sup>4</sup>, D.M.A.E. Jonkers<sup>1</sup>, A.A.M. Massee<sup>1</sup>, D. Keszthelyi<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, <sup>2</sup>Dept. of Mathematics and Statistics, Maastricht University, Maastricht, <sup>3</sup>Dept. of Psychiatry, Maastricht University Medical Center+, Maastricht, <sup>4</sup>Dept. of General practice and elderly care medicine, Maastricht University, Maastricht, the Netherlands.
- 13.18 Ledenvergadering van de NVH  
Aansluitend lunch in de expositiehal en gemodereerde postersessies

### E-learning Voeding

### Baroniezaal

- 14.00 Meer kennis over voeding bij gezondheid en ziekte!  
Dr. G.J.A. Wanten, MDL-arts, Radboudumc, Nijmegen  
Dr. J.W. Kruimel, MDL-arts, MUMC+, Maastricht  
R.G.P.J. de Jong, aios MDL, Zuyderland, Heerlen  
F. Jansen, arts-onderzoeker, Radboudumc, Nijmegen
- 14.40 Richtlijn PEG  
Dr. S.S. Gisbertz, chirurg, Amsterdam UMC  
Dr. L.P.L. Gilissen, MDL-arts, Catharina Ziekenhuis, Eindhoven
- 15.00 Einde van deze sessie

DONDERDAG 15 SEPTEMBER 2022

**Symposium Bariatrie: wat moet de MDL-arts weten**

**Baroniezaal**

Voorzitters: P. Koehestanie en S.D. Kuiken

- 15.00      **Introductie**  
*Dr. P. Koehestanie, MDL-arts, Bravis Ziekenhuis, Roosendaal  
Dr. S.D. Kuiken, MDL-arts, OLVG, Amsterdam*
- 15.05      **Overzicht bariatrische ingrepen**  
*Dr. S.M.M. de Castro, chirurg OLVG, Amsterdam*
- 15.20      **Endoscopie bij bariatrie voor dummies**  
*Dr. D.P. Hirsch, MDL-arts, Rijnstate Ziekenhuis, Arnhem*
- 15.35      **Pancreato-biliaire complicaties**  
*Dr. R.P. Voermans, MDL-arts, Amsterdam UMC*
- 15.50      **Voeding en deficiënties bij bariatrie**  
*S. Oost, Internist-vasculair geneeskundige, ZGT Almelo*
- 16.05      **Buikpijn na bariatrie**  
*K. Berghuis, PA obesitascentrum  
Dr. L.P.L. Gilissen, MDL-arts, Catharina Ziekenhuis, Eindhoven*
- 16.20      **Panel discussie**  
*Dr. P. Koehestanie, MDL-arts Bravis Ziekenhuis, Roosendaal  
Dr. S.D. Kuiken, MDL-arts, OLVG, Amsterdam*
- 16.30      **Afsluiting**

DONDERDAG 15 SEPTEMBER 2022

**Niet-alcoholische leververvetting (NAFLD)**

**Parkzaal**

Voorzitters: *M.E. Tushuizen en A.G. Holleboom*

11.15 Is NAFLD wel N-AFLD?  
*S. Meijnikman, PhD student Amsterdam UMC  
thans aios MDL, Leids Universitair Medisch Centrum*

The clock ticks: morning or evening training for NAFLD?  
*M. Schönke, postdoctoral fellow, Leids Universitair Medisch Centrum*

Fibrose voorspeller in NAFLD/NASH  
*L. Verschuren, Sr. Scientist Applied Systems Biology, TNO*

12.15 Einde van deze sessie

**Sectie Gastrointestinale Endoscopie**

**Parkzaal**

Voorzitter: *L.M.G. Moons*

12.15 How to do it - Instructievideo's

13.15 Einde van deze sessie

DONDERDAG 15 SEPTEMBER 2022

**V&VN MDL Plenair programma**

**Brabantzaal**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: *M. van der Ende-van Loon*

09.30 Opening

09.35 Digitaal fit: letterlijk en figuurlijk  
*J. Arends, internist infectioloog, directeur Happiapp*

10.05 (Acute) pancreatitis, behandeling en onderzoeksresultaten  
*Dr. R.C. Verdonk, MDL-arts, St. Antonius Ziekenhuis, Nieuwegein*

10.20 Eosinofiele oesofagitis  
*Dr. M.J. Warners, aios MDL, St. Antonius Ziekenhuis, Nieuwegein*

10.45 Koffie-/theepauze in de expositiehal

**V&VN MDL Endoscopie**

**Brabantzaal**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: *P. Terpstra*

11.15 Nieuwe PEG-richtlijn  
*Dr. L.P.L. Gilissen, MDL-arts, Catharina Ziekenhuis*

11.45 De complexe ERCP  
*Dr. R. Zoutendijk, MDL-arts, Antonius Ziekenhuis*

12.15 Einde van deze sessie, lunchpauze in de expositiehal

DONDERDAG 15 SEPTEMBER 2022

**V&VN MDL Abstracts**

**Brabantzaal**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: *T. Korpershoek*

- 12.15 The European Society of Gastroenterology and Endoscopy Nurses and Associates  
*M. Poot, voorzitter ESGENA*
- 12.20 Ondersteunt de Charlson Comorbiditeits Index zorgverleners bij de besluitvorming rondom de screeningscolonoscopie?  
*S. van Baalen, verpleegkundige in opleiding tot specialist, Erasmus MC, Rotterdam*
- 12.30 Kwaliteitsverbeterplan dieet na ERCP  
*S. Naberhuis, MDL verpleegkundige, ZGT Almelo*
- 12.40 The Dutch Inflammatory Bowel- Disease Fatigue patient self- assessment scale: a comprehensible tool with adequate psychometric properties  
*A. Stoker, verpleegkundige in opleiding tot specialist, Catharina Ziekenhuis, Eindhoven*
- 12.50 Verpleegkundige interventies bij hepatische encefalopathie  
*E. Smits, verpleegkundige, Albert Schweitzer Ziekenhuis, Dordrecht*
- 13.00 Uitreiking abstractprijs
- 13.15 Lunch in de expositiehal en gemodereerde postersessies

**V&VN MDL Endoscopie**

**Brabantzaal**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: *P. Terpstra*

- 14.00 Stentplaatsing  
*A.N. Reijm, verpleegkundig specialist, Erasmus MC, Rotterdam*
- 14.30 Endoscopische echogeleide gastro-enterostomie  
*Prof. dr. F.P. Vleggaar, MDL arts UMC Utrecht*
- 15.00 POEM  
*Prof. dr. A.J. Bredenoord, MDL-arts, Amsterdam UMC*

DONDERDAG 15 SEPTEMBER 2022

- 15.30      Upper GI bloedingen  
                Dr. N.L. de Groot, MDL-arts, Rode Kruis Ziekenhuis, Beverwijk
- 16.00      Einde van deze sessie

**V&VN MDL Chirurgie/ oncologie**

**Baroniezaal**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: A.N. Reijm

- 11.15      T1 carcinoom  
                Dr. L.M.G. Moons, MDL-arts, UMC Utrecht
- 11.45      Functionele klachten na buismaag chirurgie  
                K. Berghuis, PA bariatrische chirurgie, Catharina Ziekenhuis
- 12.15      Einde van deze sessie

**V&VN MDL Inflammatoire darmziekten**

**Parkzaal**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: R. Theeuwen

- 14.00      Chronische diarree  
                Dr. P.F. Vollebregt, MDL-arts, Amsterdam UMC
- 14.30      IBD en vermoeidheid  
                R. Lovelkyte, arts-onderzoeker, LUMC
- 15.00      IBD en arbeid  
                Dr. M.H.M. Derikx, klinisch arbeidsgeneeskundige IBD, Radboud UMC
- 15.30      IBD en seksualiteit  
                S. van der Zwet, verpleegkundig specialist, MC Leeuwarden
- 16.00      Einde van deze sessie

DONDERDAG 15 SEPTEMBER 2022

**V&VN MDL Lever & Kinder**

**Zaal 80**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: *J. Helder*

- 11.15 Van aanmelding tot chirurgie: leverdonatie bij leven  
*A. Chorley, coördinator levende donor levertransplantatieprogramma, Erasmus MC, Rotterdam*
- 11.45 Chirurgische aspecten van leverdonaties bij leven  
*Dr. R. Minnee, transplantatiechirurg, Erasmus MC, Rotterdam*
- 12.15 Einde van deze sessie

**V&VN MDL Verpleegkundig endoscopisten**

**Zaal 80**



Beroepsvereniging van zorgprofessionals

Maag Darm Lever

Voorzitter: *A. Boersen*

- 14.00 AI op de endoscopie  
*Q.E.W. van der Zander, arts-onderzoeker, Maastricht UMC*
- 14.30 Resect en discard strategie bij kleine poliepen  
*V. van der Voort, aios MDL, UMC Utrecht*
- 15.00 Endoscopische resectie technieken  
*L.W. Zwager, MDL-arts, Noordwest Ziekenhuisgroep*
- 15.30 Koud lassen bij anticoagulantia  
*Spreker volgt*
- 16.00 Einde van deze sessie

- 17** Cost-effectiveness analysis of increased adalimumab dose intervals in patients with Crohn's disease in stable remission: the randomised controlled LADI trial  
*F.M. Jansen<sup>1</sup>, R.C.A. van Linschoten<sup>2</sup>, R.W.M. Pauwels<sup>2</sup>, L.J.T. Smits<sup>1</sup>, W. Kievit<sup>3</sup>, P.J. Boekema<sup>4</sup>, R.L. West<sup>5</sup>, A.G.L. Bodelier<sup>6</sup>, I.A.M. Gisbertz<sup>7</sup>, F.H.J. Wolfhagen<sup>8</sup>, T.E.H. Römkens<sup>9</sup>, M.W.M.D. Lutgens<sup>10</sup>, A.A. van Bodegraven<sup>11</sup>, B. Oldenburg<sup>12</sup>, M. Pierik<sup>13</sup>, M.G.V.M. Russel<sup>14</sup>, N.K. de Boer<sup>15</sup>, R.C. Mallant-Hent<sup>16</sup>, P.C.J. ter Borg<sup>17</sup>, A.E. van der Meulen<sup>18</sup>, J.M. Jansen<sup>19</sup>, S.V. Jansen<sup>20</sup>, A.C.I.T.L. Tan<sup>21</sup>, F. Hoentjen<sup>1</sup>, C.J. van der Woude<sup>2</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboud UMC, Nijmegen, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, <sup>3</sup>Dept. of Health Evidence, Radboud UMC, Nijmegen, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Maxima MC, Eindhoven, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Amphia Hospital, Breda, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Bernhoven Hospital, Uden, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Elisabeth Tweesteden Hospital, Tilburg, <sup>11</sup>Dept. Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, <sup>12</sup>Dept. of Gastroenterology and Hepatology, UMC Utrecht, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC+, Maastricht, <sup>14</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Twente, <sup>15</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, <sup>16</sup>Dept. of Gastroenterology and Hepatology, Flevo Hospital, Almere, <sup>17</sup>Dept. of Gastroenterology and Hepatology, Ikazia Hospital, Rotterdam, <sup>18</sup>Dept. of Gastroenterology and Hepatology, Leiden UMC, Leiden, <sup>19</sup>Dept. of Gastroenterology and Hepatology, OLVG Hospital, Amsterdam, <sup>20</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, <sup>21</sup>Dept. of Gastroenterology and Hepatology, CW Hospital, Nijmegen, The Netherlands.*
- 18** Implications of tioguanine dosing in IBD patients with a homozygous TPMT deficiency  
*D.S. Deben<sup>1</sup>, R.H. Creemers<sup>2</sup>, K.N. Shudofsky<sup>3</sup>, B.J.C. van den Bosch<sup>4</sup>, P.J. Bus<sup>5</sup>, A. van Nunen<sup>2</sup>, L.J.J. Derijks<sup>6</sup>, A.A. van Bodegraven<sup>2</sup>, D.R. Wong<sup>1</sup>, <sup>1</sup>Dept. of Clinical Pharmacy and Toxicology, Zuyderland Medical Center, Sittard-Geleen, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Zuyderland Medical Center, Sittard-Geleen, <sup>3</sup>Dept. of Clinical Pharmacy and Toxicology, VieCuri Medical Center, Venlo, <sup>4</sup>Dept. of Clinical Genetics, Maastricht University Medical Center , Maastricht, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Laurentius Hospital Roermond, <sup>6</sup>Dept. of Clinical Pharmacy and Toxicology, Maxima Medical Center, Veldhoven, The Netherlands.*
- 19** Smoking and colitis-associated colorectal neoplasia: exploring the relationship  
*A.M. Wijnands<sup>1</sup>, S.G. Elias<sup>2</sup>, E. Dekker<sup>3</sup>, H.H. Fidder<sup>1</sup>, F. Hoentjen<sup>4</sup>, J.R. Ten Hove<sup>1</sup>, P.W.J. Maljaars<sup>5</sup>, A.E. Van der Meulen-de Jong<sup>5</sup>, E. Mooiweer<sup>6</sup>, R.J. Ouwehand<sup>1</sup>, C.Y. Ponsioen<sup>3</sup>, F.D.M. van Schaik<sup>1</sup>, J.P.D. Schultheiss<sup>1</sup>, M. Severs<sup>1</sup>, B. Oldenburg<sup>1</sup>, <sup>1</sup>Dept. Of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, <sup>2</sup>Dept. Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>4</sup>Dept. of Medicine, University of Alberta and Radboud university medical centre, Edmonton, Canada. <sup>5</sup>Dept. of Gastroenterology and Hepatology, Leiden University*

Medical Centre, Leiden, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Hospital St Jansdal, Harderwijk, The Netherlands.

- 20 Hyperferritinemia and liver iron content determined with MRI: a new role for the liver iron index  
W. Moris<sup>1</sup>, J. Verbeek<sup>2</sup>, F.C. Bakers<sup>3</sup>, E. Rombout-Sestrienkova<sup>1</sup>, A.A.M. Masclee<sup>1</sup>, G.H. Koek<sup>1</sup>, C.T.B.M. van Deursen<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, MUMC+, Maastricht, <sup>2</sup>Dept. of Hepatology, University Hospitals KU Leuven, Leuven, België. <sup>3</sup>Dept. of Radiology, MUMC+, Maastricht, The Netherlands.
- 21 Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B  
D.P.C. van der Spek, W.K. Katwaroe, L. van Kleef, S. Brakenhoff, R.A. de Man, R.J. de Knegt, A.J. van der Meer, M.J. Sonneveld, Dept. of Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam, The Netherlands.

	Postersessie V	Expositiehal
22	The measured distance between tumor cells and the peritoneal surface predicts the risk of peritoneal metastases and offers an objective means to differentiate between pT3 and pT4a colon cancer. D.D. Wisselink <sup>1</sup> , C.E.L. Klaver <sup>2</sup> , J.D.W. van der Bilt <sup>3</sup> , P.J. Tanis <sup>4</sup> , P. Snaebjornsson <sup>5</sup> , <sup>1</sup> Dept. of Gastrointestinal Surgery, Amsterdam UMC, Amsterdam, <sup>2</sup> Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, <sup>3</sup> Dept. of Gastrointestinal Surgery Flevoziekenhuis, Almere, <sup>4</sup> Dept. of Gastrointestinal Surgery, Erasmus Medical Center, Rotterdam, <sup>5</sup> Dept. of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.	
23	Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study M. Guckenberger <sup>3</sup> , P.S.N. van Rossum <sup>2</sup> , J.P. Ruurda <sup>1</sup> , R. van Hillegersberg <sup>1</sup> , <sup>1</sup> Dept. of Surgery, UMC Utrecht, Utrecht, <sup>2</sup> Dept. of Radiotherapy, UMC Utrecht, Utrecht, The Netherlands. <sup>3</sup> Dept. of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.	
24	Oligometastatic liver disease in synchronous metastatic gastric cancer: a nationwide population-based cohort study T.E. Kroese <sup>1</sup> , R. van Hillegersberg <sup>1</sup> , P.S.N. van Rossum <sup>2</sup> , J.P. Ruurda <sup>1</sup> , R. Verhoeven <sup>3</sup> , H.W.M. van Laarhoven <sup>3</sup> , <sup>1</sup> Dept. of Surgery, UMC Utrecht, Utrecht, <sup>2</sup> Dept. of Radiotherapy, UMC Utrecht, Utrecht, <sup>3</sup> Dept. of Medical Oncology, Amsterdam UMC, Amsterdam, The Netherlands.	
25	Fluorescence molecular endoscopy using cetuximab-800CW to evaluate the response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer A.M. van der Waaij <sup>1</sup> , W.T.R. Hooghiemstra <sup>1</sup> , R.Y. Gabriëls <sup>1</sup> , G. Kats-Ugurlu <sup>2</sup> , B. van Etten <sup>3</sup> , W.B. Nagengast <sup>1</sup> , <sup>1</sup> Dept. of Gastroenterology and Hepatology, UMCG, Groningen, <sup>2</sup> Dept. of Pathology, UMCG, Groningen, <sup>3</sup> Dept. of Surgery, UMCG, Groningen, The Netherlands.	

DONDERDAG 15 SEPTEMBER 2022

- 26 Presence of metabolic comorbidities is associated with reduced HCC-free survival in patients with chronic hepatitis B  
*L.A. Patmore, W.K. Katwaroe, D. van der Spek, S. Brakenhoff, A.J. van der Meer, H.L.A. Janssen, L.A. van Kleef, R.J. de Knecht, B.E. Hansen, R.A. de Man, M.J. Sonneveld, Dept. of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.*